Celldex Therapeutics, Inc. (CLDX) intrinsic value & 10-year financials
Celldex Therapeutics, Inc. (CLDX) has a Graham intrinsic value of $73.42 per share. At $27.53 on Oct 17, 2026, the stock trades 63% below that value. Over the last 10 fiscal years revenue shrank 15.2% a year to $1.5M, with an average return on invested capital of -46.8%.
- Graham intrinsic value
- $73.42
- Share price (Oct 17, 2026)
- $27.53
- Price vs Graham value
- 63% below
- Market cap
- $1.8B
- Revenue (FY2025)
- $1.5M
- Revenue growth (10-yr CAGR)
- -15.2%
- ROIC (10-yr avg)
- -46.8%
- Free cash flow (FY2025)
- -$213.7M
CLDX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.5M | -$258.8M | -$3.90 | -$213.7M | -18599.8% | -47.1% |
| FY2024 | $7.0M | -$157.9M | -$0.00 | -$159.7M | -2778.9% | -35.0% |
| FY2023 | $6.9M | -$141.4M | -$0.00 | -$109.1M | -2245.3% | -44.5% |
| FY2022 | $2.4M | -$112.3M | -$0.00 | -$105.6M | -4889.0% | -33.0% |
| FY2021 | $4.7M | -$70.5M | -$0.00 | -$62.2M | -1531.8% | -25.9% |
| FY2020 | $7.4M | -$59.8M | -$0.00 | -$42.0M | -854.1% | -49.3% |
| FY2019 | $3.6M | -$50.9M | -$0.00 | -$47.1M | -1540.2% | -60.2% |
| FY2018 | $9.5M | -$151.2M | — | -$76.0M | -1640.1% | -86.4% |
| FY2017 | $12.7M | -$93.0M | — | -$101.7M | -953.7% | -38.4% |
| FY2016 | $6.8M | -$128.5M | — | -$115.8M | -1958.7% | -48.4% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Celldex Therapeutics, Inc. is facing top-line stagnation, with revenue contracting over the decade.
Celldex Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -42.1% ROIC.
Celldex Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Celldex Therapeutics, Inc. is modeled at -15.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $73.42 per share.